27771784|t|Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival
27771784|a|The aim of this study was to evaluate whether body weight changes in patients undergoing chemotherapy for epithelial ovarian cancer (EOC) influence progression-free survival (PFS) and overall survival (OS). An analysis of 190 patients diagnosed with ovarian cancer after first-line chemotherapy was conducted. Changes in body weight were assessed by comparing measurements at baseline to those of the third and sixth cycles of chemotherapy. PFS and OS were calculated with the Kaplan-Meier method and multivariate Cox model. Significant reduction in body weight in advanced EOC was observed with no changes in early EOC. Significant differences in PFS were observed in advanced EOC patients that lost more than 5 % of their body weight (6 months), maintained weight (13 months), or gained more than 5 % of their body weight (15 months). Similarly, significant differences in OS were noted in advanced EOC at the following time points: 24.3, 42.4, and 66.2 months. No effect was reported for early EOC patients. The multivariate Cox analysis showed significant body weight changes from the first to the sixth chemotherapy cycle for PFS (HR = 0.97; 95 % CI 0.95-0.99) and OS (HR = 0.94; 95 % CI 0.91-0.97) as well as from the first to the third chemotherapy cycle for OS (HR = 0.93; 95 % CI 0.88-0.98). Body weight changes can be recognized as a prognostic factor for PFS and OS in advanced EOC patients undergoing chemotherapy. Weight loss is associated with poorer survival while weight gain improved outcomes.
27771784	0	19	Body weight changes	T033	C0005911
27771784	23	31	patients	T101	C0030705
27771784	43	55	chemotherapy	T061	C3665472
27771784	60	74	ovarian cancer	T191	C0029925
27771784	85	101	progression-free	T081	C0242792
27771784	106	122	overall survival	T081	C4086681
27771784	139	144	study	T062	C2603343
27771784	169	188	body weight changes	T033	C0005911
27771784	192	200	patients	T101	C0030705
27771784	212	224	chemotherapy	T061	C3665472
27771784	229	254	epithelial ovarian cancer	T191	C0677886
27771784	256	259	EOC	T191	C0677886
27771784	271	296	progression-free survival	T081	C0242792
27771784	298	301	PFS	T081	C0242792
27771784	307	323	overall survival	T081	C4086681
27771784	325	327	OS	T081	C4086681
27771784	333	341	analysis	T062	C0936012
27771784	349	357	patients	T101	C0030705
27771784	358	367	diagnosed	T033	C0011900
27771784	373	387	ovarian cancer	T191	C0029925
27771784	405	417	chemotherapy	T061	C3665472
27771784	433	455	Changes in body weight	T033	C0005911
27771784	499	507	baseline	T081	C1442488
27771784	540	562	cycles of chemotherapy	T061	C1302181
27771784	564	567	PFS	T081	C0242792
27771784	572	574	OS	T081	C4086681
27771784	600	619	Kaplan-Meier method	T170	C0025663
27771784	624	646	multivariate Cox model	T170	C3161035
27771784	660	684	reduction in body weight	T033	C1262477
27771784	697	700	EOC	T191	C0677886
27771784	739	742	EOC	T191	C0677886
27771784	771	774	PFS	T081	C0242792
27771784	801	804	EOC	T191	C0677886
27771784	805	813	patients	T101	C0030705
27771784	819	823	lost	T033	C1262477
27771784	847	858	body weight	T032	C0005910
27771784	862	868	months	T079	C0439231
27771784	871	888	maintained weight	T081	C0043100
27771784	893	899	months	T079	C0439231
27771784	905	911	gained	T033	C0043094
27771784	935	946	body weight	T032	C0005910
27771784	951	957	months	T079	C0439231
27771784	998	1000	OS	T081	C4086681
27771784	1024	1027	EOC	T191	C0677886
27771784	1079	1085	months	T079	C0439231
27771784	1087	1096	No effect	T080	C1301751
27771784	1120	1123	EOC	T191	C0677886
27771784	1124	1132	patients	T101	C0030705
27771784	1138	1163	multivariate Cox analysis	T170	C3161035
27771784	1183	1202	body weight changes	T033	C0005911
27771784	1231	1249	chemotherapy cycle	T061	C1302181
27771784	1254	1257	PFS	T081	C0242792
27771784	1259	1261	HR	T081	C2985465
27771784	1275	1277	CI	T081	C0009667
27771784	1293	1295	OS	T081	C4086681
27771784	1297	1299	HR	T081	C2985465
27771784	1313	1315	CI	T081	C0009667
27771784	1366	1384	chemotherapy cycle	T061	C1302181
27771784	1389	1391	OS	T081	C4086681
27771784	1393	1395	HR	T081	C2985465
27771784	1409	1411	CI	T081	C0009667
27771784	1424	1443	Body weight changes	T033	C0005911
27771784	1467	1484	prognostic factor	T201	C1514474
27771784	1489	1492	PFS	T081	C0242792
27771784	1497	1499	OS	T081	C4086681
27771784	1512	1515	EOC	T191	C0677886
27771784	1516	1524	patients	T101	C0030705
27771784	1536	1548	chemotherapy	T061	C3665472
27771784	1550	1561	Weight loss	T033	C1262477
27771784	1581	1596	poorer survival	T169	C0220921
27771784	1603	1614	weight gain	T033	C0043094
27771784	1615	1623	improved	T033	C0184511
27771784	1624	1632	outcomes	T169	C1274040